XXXX of the Breast and Responsiveness to Eribulin.

@entity1 @entity4264 @entity6023 @entity5 @entity5948 @entity20372 @entity69287 @entity3
@entity20372 ( @entity20372 ) of the breast is an uncommon @entity5 characterized by its dual differentiation into luminal cells and myoepithelial cells. In most cases these @entity5 have a benign clinical course, but distant @entity3 have been reported. We present the case of a 51-year-old @entity1 diagnosed with malignant @entity20372 . The @entity1 underwent a right modified radical mastectomy, and pathological examination confirmed the diagnosis of malignant @entity20372 . Ten months after the operation, multiple hepatic, pleural, and abdominal wall @entity3 were detected. A number of palliative chemotherapeutic agents were tried, including @entity5948 and @entity6023 . However, the disease continued to progress, and superior @entity4264 developed as a result of direct @entity5 invasion. The @entity1 received salvage eribulin monotherapy. After two cycles of this treatment, her clinical symptoms were ameliorated, and a computed tomography scan showed a partial response. @entity69287 chemotherapy was thus effective in treating malignant @entity20372 in this case.
